Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 1, 2015, Pages 63-68

  Danzig, M R ^a   Kotamarti, S ^a   Ghandour, R A ^a   Rothberg, M B ^a   Dubow, B P ^a   Benson, M C ^a   Badani, K K ^a   McKiernan, J M ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER LOCALIZATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADJUVANT THERAPY; ADVERSE EFFECTS; AGED; CANCER GRADING; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES COMPLICATIONS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; META ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS;

AGED; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 84922632590     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.47     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123.
3. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012; 61: 664-675.
4. Kattan MW, Vickers AJ, Yu C, Bianco FJ, Cronin AM, Eastham JA et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009; 115: 1005-1010.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
6. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-1876.
7. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
8. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19.
9. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: molecular and clinical aspects. Eur J Cancer 2011; 47: 819-830.
10. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942.
11. Bañez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2010; 19: 722-728.
12. Ben sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465-2475.
13. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812.
14. Ben sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
15. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011; 223: 283-294.
16. Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED, Saxena A et al. Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis 2013; 34: 2823-2832.
17. Bansal D, Undela K, D'cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.
18. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010; 116: 3389-3398.
19. Kontraros M, Varkarakis I, Ntoumas K, Deliveliotis C. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int 2013; 90: 263-269.
20. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367: 1792-1802.
21. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1427-1434.
22. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013; 37: 207-218.
23. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069-3075.
24. Penney KL, Stampfer MJ. The time is ripe for a randomized trial of metformin in clinically localized prostate cancer. J Clin Oncol 2013; 31: 3054-3055.
25. Lehman DM, Lorenzo C, Hernandez J, Wang CP. Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012; 35: 1002-1007.
26. Ritch CR, Hruby G, Badani KK, Benson MC, Mckiernan JM. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011; 108: E211-E216.
27. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511-1518.
28. Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol 2012; 36: e243-e250.
29. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-499.
30. Matafome P, Louro T, Rodrigues L, Crisóstomo J, Nunes E, Amaral C et al. Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. Diabetes Metab Res Rev 2011; 27: 54-62.
31. Woodard J, Platanias LC. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 2010; 398: 135-139.
32. ClinicalTrials.gov. Statin and prostate cancer. Available at: http://clinicaltrials.gov/ct2/results?term=statinandprostatecancer&Search=Search. Accessed 25 March 2014.
33. ClinicalTrials.gov. Metformin and prostate cancer. Available at: http://clinicaltrials.gov/ct2/results?term=metforminandprostatecancer&Search=Search. Accessed 25 March 2014.